Carbohydrate Antigen
Unlock the Future of Disease Detection: Trust Carbohydrate Antigen (CA) for Cutting-Edge Research
CAs are critical biomarkers in the intricacies of biological research. These molecular beacons, derived from complex carbohydrate structures on the cell surface, are essential in diagnosing and understanding a variety of diseases, especially cancer. As a pioneer in the field of glycoscience, CD BioGlyco provides researchers with CA products that are carefully designed to meet the highest standards of quality and reproducibility. With our products, researchers gain a deeper understanding of disease mechanisms and develop new, more accurate diagnostic reagents and innovative therapies. We introduce each type of CA product in detail. You can click on the title of each type of CA product to go to the product interface of that category or click on a specific product to go to the product details page.
CA 15-3 is a high molecular weight mucin produced by normal breast cells. It is overexpressed and abnormally glycosylated in breast cancer, lung cancer, ovarian cancer, pancreatic cancer, etc. CA 15-3 is used as a biomarker for breast cancer to monitor the occurrence and development of cancer. Scientists are studying the combination of CA 15-3 with other markers and test reagents to improve its sensitivity and specificity as a cancer biomarker. We provide clients with CA 15-3 products, which can be used for enzyme-linked immunosorbent assay (ELISA), western blotting (WB), immunogen, and control.
CA 19-9 is a sialyl Lewis (a) antigen expressed on glycoproteins and glycolipids. It is present on the carbohydrate side chains of mucin-like proteins that are specific to certain tissues and pathological conditions, especially malignant tissues and pathological conditions. CA 19-9 is used as a tumor marker to monitor disease progression and treatment response in pancreatic cancer. We provide clients with CA 19-9 products of different sources and activities, which are used to study the pathways and mechanisms that lead to the expression of CA 19-9 in malignant cells and develop corresponding therapies. Scientists also develop vaccines against tumors that express CA 19-9.
CA 125 is a high molecular weight glycoprotein with a size of more than 200 kDa, attached to carbohydrate chains on the core protein structure. It is expressed by epithelial cells derived from the coelomic epithelium, which line organs such as the ovaries, peritoneum, pleura, and pericardium. CA 125 is being evaluated as a biomarker for ovarian cancer for early detection and monitoring of ovarian cancer. We provide clients with CA 125 derived from cell culture supernatant, adenocarcinoma, E. coli, metastatic lung tissue carcinoma, etc. These products are used in combination with other methods to develop detection reagents with higher accuracy and specificity.
CA 72-4, also known as tumor-associated glycoprotein 72 (TAG-72), is a tumor marker used primarily for monitoring and diagnosing gastrointestinal cancers, particularly gastric and ovarian cancers. CA 72-4 is a glycoprotein complex that is detected in the blood, and elevated levels may indicate malignancy. CA 72-4 is quantified in the laboratory by ELISA or chemiluminescent immunoassay (CLIA). CD BioGlyco offers the following CA 72-4 to clients for use in corresponding cancer research.
We offer other types of CA products, such as alpha-fetoprotein antigen (AFP), CA 242, CA 50, carcinoembryonic antigen (CEA), and prostate-specific antigen (PSA). Understanding the role of these antigens in cancer biology allows researchers to develop targeted therapies, such as monoclonal antibodies that specifically target these antigens. New and sensitive immunoassays (such as ELISA) for detecting these antigens can be developed to improve diagnostic accuracy and provide earlier detection.
Publication
Technology: CA-125, Animal cancer models
Journal: Cancers
IF: 4.5
Published: 2021
Results: CA-125, encoded by the MUC16 gene, is highly expressed in ovarian cancer cells in more than 80% of patients, and there is an urgent need to develop new therapies to help patients with this deadly disease. Here, the authors successfully developed a conditionally replicative oncolytic adenovirus (CRAd) that only grows and destroys ovarian cancer cells expressing CA-125, but not normal cells. CRAd has a good anti-cancer effect in human ovarian cancer cells and animal cancer models and is a unique and potential treatment for ovarian cancer.
Fig.1 Generation of recombinant CRAd with MUC16 1040 bp upstream fragment to control E1A expression. (Yue, et al., 2021)
Applications
- Carbohydrate antigens are used to develop monoclonal antibodies against specific cancers for targeted cancer therapy.
- Carbohydrate antigens are used in conjunction with protein carriers to develop glycoconjugate vaccines to enhance immune responses.
- Abnormal carbohydrate antigen expression is a biomarker for autoimmune diseases, and carbohydrate antigen products are used to study disease biomarkers such as lupus and rheumatoid arthritis.
- Characterizing carbohydrate antigens and their interactions with proteins is key to understanding cell signaling and molecular pathways.
- Surface carbohydrate antigens are used to characterize and isolate specific stem cell populations, which is critical for regenerative medicine and the development of therapeutic applications.
Advantages of Us
- We provide clients with high-quality carbohydrate antigen products such as CA15-3, CA19-9, CA125, and CA72-4 to meet the research needs of different diseases.
- These products are subject to strict quality control standards to ensure the stability of quality in different experiments and applications.
- We continuously optimize the purification process to improve the purity of the product and reduce contaminants, and provide products that meet the standards of vaccine research.
- Detailed product data sheets and material safety data sheet files are attached. Contact our experts at any time to deal with difficulties and problems in the use of products.
At CD BioGlyco, we are committed to providing our clients with high-quality CA products suitable for research use to advance the development of cancer-related therapies. For more information about our products and how they can benefit your research, please visit our website or feel free to contact us. Believe that CD BioGlyco is your best partner to open up the future of biomedicine together.
References
- Yue, E.; et al. Targeting CA-125 transcription by development of a conditionally replicative adenovirus for ovarian cancer treatment. Cancers. 2021, 13(17): 4265.
- From Wikipedia: https://upload.wikimedia.org/wikipedia/commons/4/47/Lobules_and_ducts_of_the_breast.jpg.
- From Wikipedia: https://upload.wikimedia.org/wikipedia/commons/5/53/Secondary_tumor_deposits_in_the_liver_from_a_primary_cancer_of_the_pancreas.jpg.
- From Wikipedia: https://upload.wikimedia.org/wikipedia/commons/e/ed/Ovarian_carcinoma.JPG.
